| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
MRC Toxicology Unit, Hodgkin Building, University of Leicester, P. O. Box 138, Lancaster Road, Leicester LE1 9HN, United Kingdom
Tamoxifen, a rat liver carcinogen, was administered to female lambda/lacI transgenic rats at a dose of 20 mg/kg body weight by gavage for 6 weeks, and the animals were sacrificed 2 weeks later. Tamoxifen induced liver DNA adducts and caused a significant increase in mutation frequency (MF) of approximately 3-fold at the lacI gene in liver DNA. Liver DNA from animals dosed with tamoxifen at 10 mg/kg also showed a similar increase in MF. The mutations were characterized by a raised proportion of: (a) G:C to T:A transversions; (b) insertions of base pairs; and (c) deletions of pairs of G:C base pairs. These observations indicate that tamoxifen induces a distinct spectrum of mutations compared with that found in controls. Toremifene, a noncarcinogenic analogue of tamoxifen with similar estrogenic/antiestrogenic properties examined at 20 mg/kg body weight using the same dosing regime as tamoxifen was not mutagenic. A single oral dose of the rat liver carcinogen aflatoxin B1 (0.5 mg/kg) also significantly raised the MF. In conclusion, although tamoxifen is not mutagenic in regulatory short-term tests, it is a gene mutagen in the rat liver.
1 To whom requests for reprints should be addressed.
Received 9/30/96. Accepted 1/27/97.
This article has been cited by other articles:
|
|
 |
|
  S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen Cancer Res., August 1, 2003; 63(15): 4402 - 4406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, G. Gamboa da Costa, M.M. Marques, S. D. Shelton, F. A. Beland, and M. G. Manjanatha Mutations induced by {alpha}-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats Carcinogenesis, October 1, 2002; 23(10): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen Cancer Res., May 1, 2001; 61(10): 3925 - 3931. [Abstract] [Full Text]
|
|
|
|
|
|
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats Carcinogenesis, April 1, 2001; 22(4): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Davies, B. Clothier, and A. G. Smith Mutation frequency in the lacI gene of liver DNA from lambda/lacI transgenic mice following the interaction of PCBs with iron causing hepatic cancer and porphyria Mutagenesis, September 1, 2000; 15(5): 379 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sone, Y. J. Li, M. Ishizuka, Y. Aoki, and M. Nagao Increased Mutant Frequency and Altered Mutation Spectrum of the lacI Transgene in Wilson Disease Rats with Hepatitis Cancer Res., September 1, 2000; 60(18): 5080 - 5086. [Abstract] [Full Text]
|
|
|
|
|
|
E. Badia, M.-J. Duchesne, A. Semlali, M. Fuentes, C. Giamarchi, H. Richard-Foy, J.-C. Nicolas, and M. Pons Long-Term Hydroxytamoxifen Treatment of an MCF-7-derived Breast Cancer Cell Line Irreversibly Inhibits the Expression of Estrogenic Genes through Chromatin Remodeling Cancer Res., August 1, 2000; 60(15): 4130 - 4138. [Abstract] [Full Text]
|
|
|
|
|
|
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction Cancer Res., June 1, 2000; 60(11): 2887 - 2891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Okochi, N. Watanabe, Y. Shimada, S. Takahashi, K. Wakazono, T. Shirai, T. Sugimura, M. Nagao, and T. Ushijima Preferential induction of guanine deletion at 5'-GGGA-3' in rat mammary glands by 2-amino- 1-methyl-6-phenylimidazo[4,5-b]pyridine Carcinogenesis, October 1, 1999; 20(10): 1933 - 1938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White The tamoxifen dilemma Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Davies, T. W. Gant, L. L. Smith, and J. A. Styles Tamoxifen induces G:C->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene Carcinogenesis, July 1, 1999; 20(7): 1351 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tombolan, D. Renault, D. Brault, M. Guffroy, F. Perin, and V. Thybaud Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of MutaTMMice treated with 5,9-dimethyldibenzo[c,g]carbazole Carcinogenesis, July 1, 1999; 20(7): 1357 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Terashima, N. Suzuki, and S. Shibutani Mutagenic Potential of {{alpha}}-(N2-Deoxyguanosinyl)tamoxifen Lesions, the Major DNA Adducts Detected in Endometrial Tissues of Patients Treated with Tamoxifen Cancer Res., May 1, 1999; 59(9): 2091 - 2095. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
